<DOC>
	<DOCNO>NCT00429572</DOCNO>
	<brief_summary>Primary Objectives : 1 . To assess feasibility mini-allogeneic Peripheral Blood Progenitor Cell ( PBPC ) transplantation patient recurrent metastatic breast cancer . 2 . To determine success rate ( complete remission without severe toxicity death ) 100 day transplant long-term progression free survival ( PFS ) rate . 3 . To examine graft vs. breast cancer effect allogeneic PBPC transplantation .</brief_summary>
	<brief_title>Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description>If tumor shrink standard-dose chemotherapy , patient receive moderate dose chemotherapy prepare blood stem cell transplant . The drug fludarabine give vein day 1-5 . The drug melphalan give vein day 4 5 . Day 6 rest day ; drug give . The blood stem cell transplant give day 7 . Bone marrow match donor may use instead blood stem cell , particularly unrelated donor . A catheter ( tube ) place large vein chest reduce number time patient stuck needle . Researchers collect blood stem cell brother sister unrelated donor use granulocyte colony-stimulating factor ( G-CSF ) receive high-dose chemotherapy . You need enough stem cell transplantation . The drug G-CSG , tacrolimus , methotrexate give ease side effect help blood count return normal transplant . G-CSF give shot skin , start day transplant continue white blood cell count normal . Tacrolimus give vein mouth 4 7 month ; last month give , dose taper . Methotrexate give vein day 1 , 3 , 6 transplant . Day 11 methotrexate give additionally donor unrelated . Blood transfusion may need also . Antithymocyte globulin give patient receive blood bone marrow donor whose cell exactly match patient unrelated donor . Sometimes transplanted cell attack normal cell patient 's body instead cancer cell . This call graft-vs-host disease ( GVHD ) . The drug methylprednisolone give vein mouth fight GVHD occurs . Patients must stay hospital 3 4 week . Patients must stay Houston area 100 day transplant . Blood test do daily patient hospital . Blood urine test chest x-ray , computer tomography ( CT ) scan , and/or bone scan do 100 day . If sign disease 100 day , treatment stop . Patients must return clinic check-ups month first year , 3 time year 4 year , year . If disease till present 100 day , patient GVHD , patient may receive infusion donor lymphocytes vein . This treatment may repeat 3 time 8 week infusion . If disease find GVHD occurs , treatment stop . Before treatment start , patient complete exam include blood urine test . An EKG ( heart function test ) heart scan do . Patients dental exam . A test lung function do . A sample breast tissue take . This do hollow needle doctor look CT scan light tube place cut breast patient anesthesia . Herceptin give every week , Human Epidermal growth factor Receptor 2 ( HER-2 ) /neu-overexpressing tumor . Prior infusion heart test do . This investigational study . Docetaxel , Melphalan , Herceptin approve US Food Drug Administration use breast cancer . About 40 patient take part study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>Recurrent residual metastatic breast carcinoma Zubrod performance status le 2 1860 year old Related donor human leukocyte antigen ( HLA ) compatible allogeneic transplantation unrelated HLAcompatible donor . No major organ dysfunction active infection None</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>PBPC Transplantation</keyword>
	<keyword>Stem Cell Infusion</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Melphalan</keyword>
</DOC>